Related Experiment Video
Updated: Oct 21, 2026

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
Published on: October 6, 2018
The new landscape of liver transplantation: Evolving candidates, new technologies, and personalized care
Alberto Ferrarese1, Laura Marta Vivian2, Giulia Camillieri2
1Multivisceral Transplant Unit, Padova University Hospital, Padova, Italy; Department of Surgery, Oncology, Gastroenterology, Padova University, Padova, Italy.
Abstract:
Liver transplantation (LT) is entering a new era shaped by changes in disease epidemiology, candidate complexity, donor utilization, and post-transplant management. The decline of viral hepatitis-related cirrhosis, together with the rise of metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and hepatocellular carcinoma, has transformed the LT waitlist into an older, frailer, and more cardiometabolically complex population. At the same time, donation after circulatory death and machine perfusion are expanding the donor pool and redefining the boundaries of graft suitability. Candidate selection is also moving beyond traditional diagnosis-based criteria, with increasing acceptance of early LT for carefully selected alcohol-related liver disease, utility-based transplantation for acute-on-chronic liver failure, and biology-driven transplant oncology, in which HCC is established whereas selected iCCA and unresectable CRLM indications remain investigational. In parallel, artificial intelligence and machine learning are being developed as decision-support tools for candidate assessment, waitlist prioritization, donor-recipient matching, and prediction of post-transplant outcomes; prospective validation and evidence of clinical impact remain limited. Immunosuppression is facing a similar transformation, shifting from standardized lifelong exposure toward individualized, monitored minimization and immunologic risk profiling, while complete withdrawal and operational tolerance remain restricted to highly selected recipients within specialized protocols. In this Perspective, we argue that the future of LT will depend on integrating biological reserve, disease behavior, graft quality, and expected survival benefit into transparent, multidisciplinary decision-making. The central challenge will be to translate innovation into durable clinical benefit while preserving equity in access to transplantation.
Related Concept Videos
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant II: Surgical Procedure
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
